Navneet Majhail
banner
bldcancerdoc.bsky.social
Navneet Majhail
@bldcancerdoc.bsky.social
Physician-in-Chief of Blood Cancers, Sarah Cannon Cancer Network | President ASTCT 2019 | #BMTsm #CARTcell #CellTherapy
Pinned
We are hiring to add to our 60+ leukemia/cell therapy/BMT physicians across the Sarah Cannon Transplant and Cellular Therapy Network - pls direct message me to learn more about opportunities for clinical investigators and clinicians 🙏
Reposted by Navneet Majhail
I am walking at Blood Cancer United Nashville's Light The Night Walk on October 23rd. I will be walking for our patients who are an inspiration to me and our team at Sarah Cannon Cancer Network Transplant and Cellular Therapy Program at TriStar Centennial.

pages.lls.org/ltn/tn/MidTN...
Navneet's Light The Night Fundraiser
Light The Night At Blood Cancer United's, formerly LLS, Light The Night we gather as a community to celebrate, honor, and remember those touched by blood cancers. Friends, families, schools, corporate...
pages.lls.org
October 11, 2025 at 5:08 PM
I am walking at Blood Cancer United Nashville's Light The Night Walk on October 23rd. I will be walking for our patients who are an inspiration to me and our team at Sarah Cannon Cancer Network Transplant and Cellular Therapy Program at TriStar Centennial.

pages.lls.org/ltn/tn/MidTN...
Navneet's Light The Night Fundraiser
Light The Night At Blood Cancer United's, formerly LLS, Light The Night we gather as a community to celebrate, honor, and remember those touched by blood cancers. Friends, families, schools, corporate...
pages.lls.org
October 11, 2025 at 5:08 PM
It was great to catch up with fellow Cleveland Clinic expat Nate Pennell during his recent visit to Sarah Cannon Research Institute Nashville. Looking forward to his leadership and vision for cancer at BMS.
October 7, 2025 at 3:39 PM
Impactful @ascocancer.bsky.social @theaacr.bsky.social session on innovations and access challenges for gene therapy. Dr Frangoul from Sarah Cannon Cancer Network/SCRI shared experience with clinical trials of Exa-cel. Jimi Olaghere shared experience as patient #16 on a trial. #ASCO25
June 1, 2025 at 1:44 PM
@daxmd.bsky.social presents on multi-cancer early detection at #ASCO25: Highlights positive predictive value & sensitivity of reflex ctDNA methylation MCED for several cancer types in individuals with obesity. With its footprint in 20 states, Sarah Cannon Cancer Network is a pioneer in MCED studies.
June 1, 2025 at 1:37 PM
Grateful for Sarah Cannon Research Institute colleagues all over the country who work hard and collaborate to advance cancer therapeutics. Learn more about #SCRI research that is being presented at #ASCO25 #ASCO2025 www.scri.com/asco/
May 30, 2025 at 2:00 PM
👋 or 👍 if you are attending #ASCO25
May 29, 2025 at 3:40 AM
Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation @bloodadvances.bsky.social

ashpublications.org/bloodadvance...
May 27, 2025 at 6:33 PM
I am in profound awe of the closeted prostate cancer experts who have emerged on social media over the last 24-48 hrs!
May 20, 2025 at 5:00 AM
Hey regular CAR-T 🚗 , armored #CARTcell 🏎️ has entered the room!
Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure | New England Journal of Medicine www.nejm.org/doi/full/10....
Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure | NEJM
Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed an anti-CD19 enhanced (armore...
www.nejm.org
May 9, 2025 at 12:50 PM
Reposted by Navneet Majhail
Applications are open for the 2026 International Trainee Observership Program. One international trainee from a low/mid-income country will participate in 4-week-long observership at the @uofcahealth.bsky.social.

📆 Deadline to apply: Friday, June 13
ow.ly/Ih0650VK0vn #MedSky #HCT #celltherapy
May 6, 2025 at 5:26 PM
Congrats to Dr Stephen Strickland from Sarah Cannon Research Institute at TriStar Centennial Medical Center, Nashville for presenting first-in-human results of SENTI-202 (CD33/FLT3 off-the-shelf CAR NK #celltherapy) in heme malignancies/AML #AACR25
www.aacr.org/about-the-aa...
Off-the-shelf CAR Natural Killer Cell Therapy with Logic Gates Elicits Complete Remissions in Relapsed or Refractory Blood Cancers
Several patients with AML, who were treated with SENTI-202 experienced a complete remission after not responding to or having relapsed following prior treatments, according to results presented at the...
www.aacr.org
April 28, 2025 at 3:09 AM
Medicine Spares Cancer Patients From Grisly Surgeries and Harsh Therapies www.nytimes.com/2025/04/27/h...
Immunotherapy Drug Spares Cancer Patients From Grisly Surgeries and Harsh Therapies
For a limited group of cancer patients who have solid tumors in the stomach, rectum, esophagus and other organs, an immunotherapy trial offered stunning results.
www.nytimes.com
April 28, 2025 at 2:58 AM
🙏 for sharing @jameabraham.bsky.social - we share our learnings from Sarah Cannon Transplant and Cellular Therapy Network outpatient #CARTcell program (200+ patients treated in 2024)
Excellent review article by @bldcancerdoc.bsky.social Outpatient Administration of Chimeric Antigen Receptor T-Cell Therapy Using Remote Patient Monitoring | JCO Oncology Practice ascopubs.org/doi/10.1200/... @acochran12733.bsky.social @oncoalert.bsky.social
April 19, 2025 at 11:56 PM
Getting a lot of questions from our immunocompromised transplant/#CARTcell patients about measles vaccination with the recent uptick in outbreaks across the US; Resurfacing 2019 @astct.bsky.social guideline by @pergamic.bsky.social and colleagues www.astctjournal.org/article/S108...
Preventing Measles in Immunosuppressed Cancer and Hematopoietic Cell Transplantation Patients: A Position Statement by the American Society for Transplantation and Cellular Therapy
Until recently, measles exposures were relatively rare and so, consequently, were an afterthought for cancer patients and/or blood and marrow transplant recipients and their providers. Declines in mea...
www.astctjournal.org
April 15, 2025 at 5:38 PM
Had a great 1 1/2 days with new/emerging transplant and cellular therapy leaders at @astct.bsky.social Leadership Course; future of transplant and cell therapy is strong in the hands of our very talented young physician and administrative leaders
April 12, 2025 at 1:59 AM
Foundation for the Accreditation of Cellular Therapy is organizing a community #CART working group to facilitate broader utilization of its accreditation standards for cell therapies - important step towards providing high-quality care to patients in the community factglobal.org/education-an...
Press Release
PRESS RELEASE OMAHA, Neb. - The Foundation for the Accreditation of Cellular Therapy (FACT) is announcing the formation of a ‘Community CAR T Working Group’ (working group) to discuss and propose cl...
factglobal.org
April 11, 2025 at 7:53 PM
Dr David Johnson reprises 7 dictums for oncologists on what NOT to do for grand rounds:
- Microscopic mayhem
- TNM torture
- Mechanism of action meltdown
- Dosage deadlock
- Criteria catatonia
- Kaplan Meier killer
- Lymph node lobotomy
@ascocancer.bsky.social JOP ascopubs.org/doi/10.1200/...
An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last | JCO Oncology Practice
ascopubs.org
April 7, 2025 at 8:45 PM
Academic Writing: Who is the Audience and What is the Message? Dr Weisdorf challenges us to consider: Which papers stated something new? Which challenged existing dogma or changed the field? Which were really important over time? @astct.bsky.social www.astctjournal.org/article/S266...
Academic Writing: Who is the Audience and What is the Message?
“The Secret is Comprised in Three Words–Work, Finish, Publish”Michael Faraday
www.astctjournal.org
April 6, 2025 at 3:21 PM
Huge loss for the cell and gene therapy community. Dr Marks had been at the forefront of innovating US’s regulatory framework to ensure access to these transformative therapies.
March 29, 2025 at 1:46 PM
Sarah Cannon Transplant and Cellular Therapy Registry work led by Drs Rao and Battiwalla comparing bendamustine vs. Flu/Cy LD chemo prior to #CART in #Lymphoma. This was done during period of Flu shortage. No difference in OS, PFS, CRS, ICANS.
www.astctjournal.org/article/S266...
Comparative Efficacy of Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion before Chimeric Antigen Receptor T-Cell Therapy in Lymphoma
Chimeric antigen receptor T-cell (CAR-T) therapy is a widely adopted treatment for relapsed/refractory non-Hodgkin lymphomas (NHLs)1. FDA-approved CAR-T products for large B-cell lymphoma (LBCL) inclu...
www.astctjournal.org
March 24, 2025 at 11:16 PM
How to do gene therapy for sickle cell disease and thalassemia - from Dr Frangoul et al at our pediatric Sarah Cannon TCT Program at TriStar Centennial in Nashville. #GeneTherapy #SickleCell @astct.bsky.social

www.sciencedirect.com/science/arti...
Best Practices in Gene Therapy for Sickle Cell Disease and Transfusion-dependent β-Thalassemia
Sickle cell disease (SCD) and transfusion-dependent β-thalassemia (TDT) are inherited blood disorders caused by pathogenic variants of the β-globin ge…
www.sciencedirect.com
March 19, 2025 at 2:54 PM
Beer, wine, and transplant. I have always enjoyed these reflections from Dr McCann in Bone Marrow Transplant. www.nature.com/articles/s41...
Guinness 0.0: a miracle! - Bone Marrow Transplantation
Bone Marrow Transplantation - Guinness 0.0: a miracle!
www.nature.com
March 11, 2025 at 12:04 PM